Darren S. Cline

CIK: 0001633639

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

PLRX

PLIANT THERAPEUTICS, INC.

Director

PYXS

Pyxis Oncology, Inc.

Director

XENE

Xenon Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

PLRX
PLIANT THERAPEUTICS, INC.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
PYXS
Pyxis Oncology, Inc.
Mar 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
45.9K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Restricted Share Units
Direct
20K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Share Option (Right to Buy)
Direct
40K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 23, 2025
Award(A)
Share Option (Right to Buy)
Direct
185.8K shares-
PLRX
PLIANT THERAPEUTICS, INC.
Jun 5, 2025
Award(A)
Common Stock (Right to Buy)
Direct
30K shares-
PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
37K shares at avg. $0.98-

		Type	Shares	Price		Ownership
Jun 11, 2026	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Mar 24, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	45,867	-	-	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	20,000	-	-	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	40,000	-	-	Direct
Jun 23, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	185,800	-	-	Direct
Jun 5, 2025	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Common Stock (Right to Buy)	30,000	-	-	Direct
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	36,979	$0.98	-	Direct

1-7 of 7 transactions

About Cline Darren S

Cline Darren S (SEC CIK 0001633639) files insider reports with the SEC as Director of PLIANT THERAPEUTICS, INC. (PLRX), Director of Pyxis Oncology, Inc. (PYXS) and Chief Commercial Officer of Xenon Pharmaceuticals Inc. (XENE).

Signal8 holds 7 ownership filings by Cline Darren S (1 Form 3, 6 Form 4), filed between Apr 2, 2025 and Jun 12, 2026. Those filings report 7 transactions, from Mar 31, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cline Darren S's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Cline Darren S

Jun 11, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
Mar 24, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Jan 9, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Jun 23, 2025: Grant or award of XENE derivative securities (Form 4, code A).
Jun 5, 2025: Grant or award of PLRX derivative securities (Form 4, code A).

Other insiders filing for PLIANT THERAPEUTICS, INC. (PLRX)

Raben David, Chief Medical Officer
Iannone Robert, Director
Borellini Flavia, Director
CROWELL GAYLE A, Director
MCCOURT Thomas A, Director
Krognes Steve E., Director

How to read Form 4 transaction codes